...
首页> 外文期刊>Cancer Cell International >High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
【24h】

High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas

机译:EZH2高表达与小儿软组织肉瘤转移性疾病相关

获取原文
           

摘要

Background Enhancer of Zeste Drosophila Homologue 2 (EZH2) is a key regulator of transcription as a member of polycomb repressive complex 2 (PRC2) which exerts repression of downstream genes and is correlated to invasiveness and progression of different tumours. Therefore, we evaluated the expression of PRC2 proteins in pediatric soft tissue sarcoma (rhabdomyosarcoma, RMS and extraosseous Ewing sarcoma, EES) correlating them to the clinical outcome of the patients. Methods We analyzed PRC2 protein expression by quantitative real time PCR, western blotting and immunohistochemistry in 17 soft tissue sarcomas (11 RMS and 6 EES) enrolled at Paediatric Oncology Units of the Second University of Naples. Expression analysis was performed for EZH2, SUZ12 and EED. Results Enhancer of Zeste Drosophila Homologue 2 was expressed with a different degree in 60?% of samples. Interestingly, the magnitude of EZH2 up regulation was significantly higher in patients presenting lymph node and/or distant metastases at the diagnosis. Moreover, patients overexpressing EZH2 had a lower probability of survival compared to patients negative or with low EZH2 expression. Conclusions Our study suggests that high EZH2 expression is associated to increased aggressiveness of the disease. Therefore, drugs that control its activity could be potentially used in the epigenetic target treatment of tumors with these alterations.
机译:Zeste果蝇同源物2(EZH2)的背景增强子是转录的关键调节剂,是多梳抑制复合物2(PRC2)的成员,该复合物可抑制下游基因,并与不同肿瘤的侵袭性和进展相关。因此,我们评估了PRC2蛋白在儿科软组织肉瘤(横纹肌肉瘤,RMS和骨外尤因肉瘤,EES)中的表达,并将其与患者的临床结果相关联。方法我们通过定量实时荧光定量PCR,蛋白质印迹和免疫组织化学分析了那不勒斯第二大学儿科肿瘤学分会的17个软组织肉瘤(11 RMS和6 EES)中PRC2的蛋白表达。对EZH2,SUZ12和EED进行了表达分析。结果Zeste果蝇同源物2的增强子在60%的样品中以不同的程度表达。有趣的是,在诊断时出现淋巴结转移和/或远处转移的患者,EZH2上调的幅度明显更高。此外,与阴性或EZH2表达低的患者相比,过表达EZH2的患者生存率较低。结论我们的研究表明,高EZH2表达与疾病侵袭性增加有关。因此,通过这些改变,控制其活性的药物可潜在地用于肿瘤的表观遗传学靶标治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号